Development of a liposomal formulation of a TKI: the active loading of erlotinib.HCl
Cindy Schelker, Victoria Trap, Gerrit Borchard, Patrycja M. Nowak-Sliwinska
This study develops a liposomal formulation of erlotinib.HCl, demonstrating successful active loading and highlighting differences in toxicity and uptake between 2D cell lines and patient-derived organoids.
bioRxiv · Jun 6, 2025 · PreprintCancer Biology